logo
How to Do a Sinus Flush at Home

How to Do a Sinus Flush at Home

Health Line03-06-2025
Nasal irrigation with a saline solution can help clear your nasal passages. Following safety tips can help prevent infection.
Nasal irrigation, also called saltwater sinus flush, is a safe and simple remedy for nasal congestion and sinus irritation that just about anyone can do at home.
A 2022 review of 69 studies concluded that nasal saline treatment is effective for treating most sinonasal diseases.
Read on to learn more about what a sinus flush is and if you might benefit from it.
What is a sinus flush?
A sinus flush, also called nasal irrigation, is a process of sending sterile (very clean) water into one side of your nose, through your sinus passages, and out the other side of your nose.
It's usually done with saline, which is just a fancy term for salt water. When rinsed through your nasal passages, saline can wash away allergens, mucus, and other debris, and help to moisten the mucous membranes.
Some people use a device called a Neti pot to help deliver the salt water to the nasal cavities, but you can also use squeeze bottles or bulb syringes.
A sinus flush is generally safe. However, there are a few important safety instructions to be aware of before you try it.
How do you do a sinus flush?
The first step to flushing your sinuses is to create a saline solution. Typically, this is done by mixing warm, sterile water with pure salt, known as sodium chloride, to create an isotonic solution — or slightly salty water.
While you can create your own saline solution at home, you can also purchase sterile, over-the-counter premixed saline packets.
It's crucial to use sterile water for this step. Never use water directly from your tap for a nasal flush without sterilizing it first. This is due to the risk of a rare but serious infection with a parasitic amoeba called Naegleria fowleri. If this amoeba enters the sinuses, it makes its way to the brain and causes a serious infection that can be life threatening.
You can sterilize your water by boiling it for a minute and then allowing it to cool. Never use hot water – always let it cool to at least room temperature.
To clear your sinuses, follow these steps:
Stand with your head over a sink or in the shower and tilt your head to one side.
Using a squeeze bottle, bulb syringe, or Neti pot, pour or squeeze the saline solution slowly into the upper nostril.
Allow the solution to pour out of your other nostril and into the drain. Breathe through your mouth, not your nose, at this time.
Repeat on the opposite side.
Try not to let the water go down the back of your throat. You may need to adjust your head position until you find the correct angle.
Gently blow your nose into a tissue when you're done to clear out any mucus.
If you've recently had sinus surgery, resist the urge to blow your nose for 2 weeks following the procedure.
Are there tips to do it safely?
You may do sinus flushing along with other medications, like antihistamines or decongestants, that you take. A sinus flush carries a small risk of infection and other side effects, but these risks can be easily avoided by following a few simple safety rules:
Wash your hands before the sinus flush.
Don't use tap water. Instead, use distilled water, filtered water, or water that has been previously boiled and cooled.
Clean out your neti pot, bulb, or squeeze bottle with hot, soapy, and sterile water or run it through the dishwasher after each use. Allow it to dry completely.
Avoid using cold water, especially if you've just had sinus surgery. For people who recently had surgery for chronic sinusitis, there's a risk of developing bony growths in the nose called paranasal sinus exostoses (PSE) if you use a cold solution.
Avoid using very hot water.
Throw away the saline solution if it appears cloudy or dirty.
Don't perform nasal irrigation on infants.
Don't do a saline sinus flush if you have a facial wound that hasn't healed, a neurologic condition, or musculoskeletal problems that put you at a higher risk of accidentally breathing in the liquid.
What are the risks and side effects of doing a sinus flush?
As mentioned above, failing to use sterile water carries a small risk of infection with a dangerous parasite called Naegleria fowleri. Symptoms of an infection with this parasite include:
severe headache
stiff neck
fever
altered mental status
seizures
coma
Boiling your water for at least a minute and then allowing it to cool before mixing in the salt should be sufficient to kill the parasite and prevent infection.
If done properly, a sinus flush shouldn't cause any major side effects. Though you may experience some mild effects, including:
stinging in the nose
sneezing
sensation of ear fullness
nosebleeds, though this is rare
If you find that a sinus flush is particularly uncomfortable, try lowering the amount of salt in the solution.
Keep in mind that some bloody nasal discharge may occur for a few weeks following a sinus surgery. This is normal and should improve over time.
Do sinus flushes work?
Several studies have shown the effectiveness of nasal irrigation for treating acute and chronic sinusitis and allergies.
Doctors most often recommend using saline sinus irrigation for chronic sinusitis. In one older study from 2009, patients with chronic sinus symptoms who used saline sinus irrigation once daily reported a 64% improvement in overall symptom severity and a significant improvement in quality of life after 6 months.
Research supporting the use of saline flush to treat allergies or the common cold is less definitive. One recent review of clinical trials in people with allergic rhinitis found that while using a saline solution appeared to improve symptoms compared to not using a saline sinus flush, the quality of evidence was low, and further research is needed.
How often should you flush?
It's fine to do a sinus flush occasionally if you're experiencing a bout of nasal congestion from a cold or allergies.
Start with one irrigation per day while you have nasal congestion or other sinus symptoms. If you feel that it is helping your symptoms, repeat the irrigation up to three times per day.
Some people continue to use it to prevent sinus issues even when they don't have symptoms. However, some doctors warn that regular use of nasal irrigation may actually increase the risk of sinus infection. Routine use may also hinder some protective features of the mucus membrane lining the nasal passages and sinuses.
More research is needed to clarify any long-term side effects of regular saline sinus flushes. At the moment, it's probably best to limit use to when you're experiencing sinus symptoms, or to ask for your doctor's advice.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health
BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

Yahoo

time6 minutes ago

  • Yahoo

BrainsWay Acquires Minority-Stake in Axis Integrated Mental Health

The Investment is part of BrainsWay's ongoing strategy to acquire minority positions in leading U.S. mental health providers to help them raise awareness for and expand access to transformative care BURLINGTON, Mass. and JERUSALEM, Aug. 20, 2025 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) ('BrainsWay' or the 'Company'), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced that it has entered into a strategic equity financing agreement with Axis Management Company, Inc. ('Axis Integrated Mental Health' or 'Axis'), a management services organization servicing several mental health clinics in Colorado. Under the terms of the agreement, BrainsWay will invest $2.3 million initially, and an additional potential $1 million milestone-based investment, for a minority position in Axis in the form of a preferred, annually compounding security. The agreement also provides for a redemption mechanism relating to the shares. 'Our minority-stake investment in Axis follows our previous investment in Stella, and is part of BrainsWay's broader initiative to accelerate access to and awareness of innovative mental health treatments, including Deep TMS Therapy, while continuing to maintain our core focus on advancing our scientific and technological capabilities to ensure best-in-class support for all our customers. Within this strategy, our investments provide capital injections into high performing healthcare providers, which then allows these businesses to invest in growth drivers and launch new locations,' said Hadar Levy, Chief Executive Officer of BrainsWay. 'We see tremendous opportunities for these healthcare providers to offer expanded services and grow their businesses once they secure the necessary capital.' 'Axis offers a robust clinical services platform and is committed to achieving rapid growth and excellent patient outcomes. We are thrilled to support and collaborate with them as their business continues to scale from a well-respected regional platform to one with a larger footprint, enhancing their delivery of life-changing care to additional patients,' concluded Mr. Levy. 'Our partnership with BrainsWay was born out of a mutual desire to deliver the best cutting-edge mental health treatments to the communities we serve,' stated Chris Perez, Chief Executive Officer of Axis. 'Given the peerless reputation of BrainsWay and its proprietary Deep TMS technology, we realize the value this strategic partnership will provide as we further advance in our mission of putting patients first through our best-in-class support.' About BrainsWay BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS™) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal clinical studies demonstrating clinically proven efficacy. Current indications include major depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with operations in the United States and Israel, BrainsWay is committed to increasing global awareness of and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit About Axis Axis Integrated Mental Health services its leading mental health practices, which are dedicated to transforming lives through a truly comprehensive, integrative model of care. With a team of board-certified specialists combining modern psychiatry and psychotherapy with advanced treatments including Deep TMS™ and Spravato®, Axis utilizes an evidence-based, holistic therapeutic approach to treat patients, all through a single, coordinated care experience under one roof. For more information, please visit Forward-Looking Statement This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words 'intends,' 'may,' 'will,' 'plans,' 'expects,' 'anticipates,' 'projects,' 'predicts,' 'estimates,' 'aims,' 'believes,' 'hopes,' 'potential' or similar words, and also includes any financial guidance and projections contained herein. These forward-looking statements and their implications are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In addition, historical results or conclusions from scientific research and clinical studies do not guarantee that future results would suggest similar conclusions or that historical results referred to herein would be interpreted similarly in light of additional research or otherwise. The following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: the failure of our investments in management services organizations and/or other clinic-related entities to produce profitable returns; inadequacy of financial resources to meet future capital requirements; changes in technology and market requirements; delays or obstacles in launching and/or successfully completing planned studies and clinical trials; failure to obtain approvals by regulatory agencies on the Company's anticipated timeframe, or at all; inability to retain or attract key employees whose knowledge is essential to the development of Deep TMS products; unforeseen difficulties with Deep TMS products and processes, and/or inability to develop necessary enhancements; unexpected costs related to Deep TMS products; failure to obtain and maintain adequate protection of the Company's intellectual property, including intellectual property licensed to the Company; the potential for product liability; changes in legislation and applicable rules and regulations; unfavorable market perception and acceptance of Deep TMS technology; inadequate or delays in reimbursement from third-party payers, including insurance companies and Medicare; inability to commercialize Deep TMS, including internationally, by the Company or through third-party distributors; product development by competitors; inability to timely develop and introduce new technologies, products and applications, which could cause the actual results or performance of the Company to differ materially from those contemplated in such forward-looking statements. Any forward-looking statement in this press release speaks only as of the date of this press release. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. More detailed information about the risks and uncertainties affecting the Company is contained under the heading 'Risk Factors' in the Company's filings with the U.S. Securities and Exchange Commission. Contacts: BrainsWay:Ido MaromChief Financial Investors:Brian RitchieLifeSci Advisors LLCbritchie@ in to access your portfolio

Share your wedding anniversary with The Oklahoman's readers
Share your wedding anniversary with The Oklahoman's readers

Yahoo

time6 minutes ago

  • Yahoo

Share your wedding anniversary with The Oklahoman's readers

Oklahoma couples celebrating 50 years or more of marriage can have their photo shared on Publication of anniversary photos on The Oklahoman's anniversary web page is free. To be included online, send an email to DLindauer@ with 'Anniversary' in the subject line. For free online announcements, email photos with your anniversary information at least two weeks before the anniversary. Only paid anniversary announcements will be published in The Oklahoman's print edition. Place your celebration announcement at This article originally appeared on Oklahoman: Celebrate your 50th wedding anniversary with The Oklahoman Solve the daily Crossword

First PRIZM Study Participant Enrolled in Tisento Therapeutics' Open-Label Extension Study in MELAS
First PRIZM Study Participant Enrolled in Tisento Therapeutics' Open-Label Extension Study in MELAS

Yahoo

time35 minutes ago

  • Yahoo

First PRIZM Study Participant Enrolled in Tisento Therapeutics' Open-Label Extension Study in MELAS

Participants Who Complete Treatment in Global Phase 2b PRIZM MELAS Study Are Eligible to Enroll CAMBRIDGE, Mass., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Tisento Therapeutics today announced that the first participant has enrolled in the company's open-label extension study in MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like Episodes). The extension study (NCT06961344) is evaluating the long-term safety and tolerability of zagociguat in individuals with MELAS who complete treatment in the global Phase 2b PRIZM study, which is expected to complete screening in the next months. The extension study is intended to provide uninterrupted access to zagociguat for clinical trial participants for up to two years and evaluate the long-term safety of zagociguat. 'We're pleased to reach the important milestone of enrolling the first PRIZM study participant into our open-label extension study,' said Peter Hecht, Ph.D., chief executive officer of Tisento. 'Enthusiastic engagement by MELAS patients and physicians is powering momentum in our development program, and we look forward to completing PRIZM enrollment in the next few months.' The PRIZM study is actively enrolling in the U.S., Canada, Australia, United Kingdom, Italy, and Germany, and interested individuals are encouraged to discuss participation with their physician. PRIZM is evaluating the impact of zagociguat treatment on fatigue, cognitive performance, and other key aspects of MELAS. The clinical outcome assessments and endpoint strategy for the PRIZM study were informed by Tisento's interview study in which individuals living with MELAS described the symptoms and impacts of the disease that are most important to them. Participants who complete treatment in PRIZM have the opportunity to enroll in the open-label extension study. About the PRIZM Study PRIZM – a Phase 2b Randomized, Placebo-Controlled Trial Investigating Zagociguat in MELAS – is evaluating the efficacy and safety of oral zagociguat 15 mg or 30 mg compared to placebo when administered once-daily for 12 weeks in participants with genetically and phenotypically defined MELAS. The PRIZM study has a crossover design, with two 12-week treatment periods separated by a 4-week washout period. All participants will receive zagociguat during one of the 12-week periods and placebo during the other. Participants who complete treatment in the study have the opportunity to enroll in an open-label extension study. The global PRIZM study is now enrolling approximately 44 participants at mitochondrial disease centers of excellence in the U.S., Italy, Germany, United Kingdom, Australia, and Canada. For more information, please visit or (NCT06402123). Interested individuals can also reach out to their physicians for participation details. About Zagociguat Zagociguat is a once-daily, oral, clinical-stage investigational medicine with potential to positively impact both peripheral and central nervous system manifestations of mitochondrial diseases. Zagociguat stimulates soluble guanylate cyclase (sGC), an enzyme that is found in virtually every cell in every tissue of the body and is part of a system of cellular mechanisms that control critical physiological functions including neuronal function and blood flow. A first-in-class, brain-penetrant sGC stimulator, zagociguat is hypothesized to rebalance dysregulated cellular pathways in MELAS. By restoring cellular functions that support mitochondria, zagociguat may help restore mitochondrial energy production and physiological function. In a Phase 2a study in patients with MELAS, zagociguat exhibited a favorable safety profile, exposure throughout the body including in the central nervous system, and improvements in neuronal function, mitochondrial function, and blood flow in the brain. Zagociguat is currently being evaluated as a treatment for MELAS in the Phase 2b PRIZM study. Zagociguat received Fast Track designation from the U.S. Food and Drug Administration for the treatment of MELAS. Fast Track is a process designed to facilitate the development and potentially expedite the review of medicines to treat serious conditions and fill an unmet medical need, with the goal of getting important new drugs to patients earlier. For more information, visit About Tisento Therapeutics Tisento Therapeutics, a privately held biotech company, is developing novel medicines to treat diseases with significant unmet need, beginning with MELAS and other genetic mitochondrial diseases. Ti sento means 'I hear you' in Italian; our approach to innovation begins with listening to patients and then channeling what we learn into decisive actions that shape our research and clinical programs. Tisento is guided by a high-caliber internal team of biopharma veterans and an extensive external network of expert physicians, patient advocacy groups, researchers, industry-leading vendors, and other close collaborators who are partners in our mission to develop meaningful treatments for mitochondrial diseases. Learn more at our website, or connect with us on LinkedIn, Facebook, X (@tisentotx), or Bluesky. Contact Tisento Media RelationsJessi Rennekamp, Astrior CommunicationsEmail: jessi@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store